Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPICE-M: Pip/Tazo vs Meropenem for AmpC BSI
NCT05355350Phase 4Withdrawn
- Sponsor
- Rambam Health Care Campus
- Start
- Jul 2022
- Primary completion
- Jul 2025
- Modality
- Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 4 trial of piperacillin + tazobactam in Bacteremia, sponsored by Rambam Health Care Campus. Planned start Jul 2022; status: withdrawn.
02
Drugs
piperacillin + tazobactam
03
Conditions
Bacteremia
Beyond the preview
Go deeper on NCT05355350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05355350.